What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary areas of investigation include Cancer research, Genetics, Gene, Genomics and DNA methylation.
His Cancer research research is multidisciplinary, incorporating elements of Somatic cell, Transcriptome, Cell cycle, Prostate cancer and Adenocarcinoma.
His Gene research includes themes of Melanoma and Subclass.
The various areas that Nikolaus Schultz examines in his Genomics study include Computational biology and DNA mismatch repair.
His work deals with themes such as Serous fluid, Microsatellite instability, KRAS, microRNA and ATRX, which intersect with DNA methylation.
His studies deal with areas such as Ovarian carcinoma and Serous carcinoma as well as Serous fluid.
His most cited work include:
- Comprehensive molecular portraits of human breast tumours (7253 citations)
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data (7137 citations)
- Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal (6440 citations)
What are the main themes of his work throughout his whole career to date?
Nikolaus Schultz focuses on Cancer research, Internal medicine, Oncology, Cancer and Gene.
His Cancer research study combines topics in areas such as DNA methylation, Mutation, PI3K/AKT/mTOR pathway, PTEN and Prostate cancer.
His DNA methylation research integrates issues from microRNA and Serous fluid.
He has researched Oncology in several fields, including Bladder cancer, Clinical trial, Pathology, Metastasis and Adenocarcinoma.
His research in Cancer intersects with topics in Computational biology, Bioinformatics and Genomics.
Gene is a subfield of Genetics that Nikolaus Schultz explores.
He most often published in these fields:
- Cancer research (32.96%)
- Internal medicine (30.45%)
- Oncology (27.37%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (30.45%)
- Oncology (27.37%)
- Cancer (22.35%)
In recent papers he was focusing on the following fields of study:
Nikolaus Schultz mainly investigates Internal medicine, Oncology, Cancer, Cancer research and Chemotherapy.
The Oncology study combines topics in areas such as Bladder cancer, Clinical trial, Hazard ratio, Colorectal cancer and Cohort.
His Cancer research is multidisciplinary, relying on both Computational biology, DNA sequencing and Genomics.
His Genomics study which covers Extent of resection that intersects with Adenocarcinoma.
His Cancer research research is multidisciplinary, incorporating perspectives in Transcriptome, Renal cell carcinoma, DNA repair, Platinum chemotherapy and Prostate cancer.
Nikolaus Schultz interconnects Prostate, Gene, Immune system and Circulating tumor cell in the investigation of issues within Prostate cancer.
Between 2019 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. (33 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His main research concerns Internal medicine, Oncology, Cancer, Genetics and Computational biology.
Many of his research projects under Internal medicine are closely connected to FANCA with FANCA, tying the diverse disciplines of science together.
The concepts of his Oncology study are interwoven with issues in Disease, Hazard ratio, Colorectal cancer, Prostate cancer and Cohort.
His study in the fields of Metastatic breast cancer, Precision oncology and Estrogen receptor under the domain of Cancer overlaps with other disciplines such as Structure.
His Computational biology research incorporates elements of Matching, Meta-analysis, Relevance and Genomics.
His study in Gene is interdisciplinary in nature, drawing from both Rare cancer and Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
